Cargando…

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers

HER2-positive (HER2+) breast cancer is defined by HER2 oncogene amplification on chromosome 17q12 and accounts for 15–20% population of breast-cancer patients. Therapeutic anti-HER2 antibody such as trastuzumab is used as the first-line therapy for HER2-positive breast cancers. However, more than 50...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuchukulla, Ratnakar Reddy, Hwang, Injeoung, Park, Sang Won, Moon, Sojeong, Kim, Suhn Hyung, Kim, Sumin, Chung, Hwan Won, Ji, Mi-Jung, Park, Hyun-Mee, Kong, Gu, Hur, Wooyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506414/ https://www.ncbi.nlm.nih.gov/pubmed/36145262 http://dx.doi.org/10.3390/ph15091041

Ejemplares similares

Promising 2,6,9-Trisubstituted Purine Derivatives for Anticancer Compounds: Synthesis, 3D-QSAR, and Preliminary Biological Assays
por: O. Salas, Cristian, et al.
Publicado: (2019)

Synthesis and Pharmacophore Modelling of 2,6,9-Trisubstituted Purine Derivatives and Their Potential Role as Apoptosis-Inducing Agents in Cancer Cell Lines
por: Calderón-Arancibia, Jeannette, et al.
Publicado: (2015)

New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile
por: Lambertucci, Catia, et al.
Publicado: (2007)

Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia
por: Bertrand, Jeanluc, et al.
Publicado: (2022)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD Inhibitors
por: Tomanová, Monika, et al.
Publicado: (2022)

Locked nucleic acid real-time polymerase chain reaction method identifying two polymorphisms of hepatitis B virus genotype C2 infections, rt269L and rt269I
por: Kim, Kijeong, et al.
Publicado: (2023)

269. Clinical Characteristics and Outcomes of Persistent Staphylococcus aureus Bacteremia
por: Yang, Eunmi, et al.
Publicado: (2020)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Production and decay of $^{269}$110
por: Hofmann, S, et al.
Publicado: (1994)

Reorienting the Fab Domains of Trastuzumab Results in Potent HER2 Activators
por: Scheer, Justin M., et al.
Publicado: (2012)

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer
por: Seo, An Na, et al.
Publicado: (2016)

Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer
por: Kim, Nalee, et al.
Publicado: (2023)

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
por: Kim, Chan, et al.
Publicado: (2017)

Phosphorylation of islet-1 serine 269 by CDK1 increases its transcriptional activity and promotes cell proliferation in gastric cancer
por: Shi, Qiong, et al.
Publicado: (2021)

PS269. Epidemiology of Completed Suicide in Different Blood Alcohol Concentration: a Nationwide Autopsy-based Study
por: Lee, Jae Won, et al.
Publicado: (2016)

Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors
por: Zhang, Gaomin, et al.
Publicado: (2018)

A Relay Strategy Actuates Pre-Existing Trisubstituted Olefins in Monoterpenoids for Cross-Metathesis with Trisubstituted Alkenes
por: Bahou, Karim A., et al.
Publicado: (2020)

Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis
por: Park, Joo-Hwan, et al.
Publicado: (2022)

AB269. Optimizing recovery of potency and continence during radical prostatectomy
por: Kim, Sae Woong
Publicado: (2016)

269 Refractory Chronic Urticaria Treated with Omalizumab
por: Saenz, Martinez, et al.
Publicado: (2012)

Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors
por: Weitensteiner, Sabine B., et al.
Publicado: (2013)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
por: Park, Soeun, et al.
Publicado: (2022)

Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance
por: Ahn, Sung Hyun, et al.
Publicado: (2015)

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016)

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
por: Yi, Jun Ho, et al.
Publicado: (2016)

Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment
por: Yoon, Sung Hyun, et al.
Publicado: (2016)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials
por: Norcross, Neil R., et al.
Publicado: (2016)

Iridium-catalyzed enantioconvergent hydrogenation of trisubstituted olefins
por: Peters, Bram B. C., et al.
Publicado: (2022)

Recent Advances in the Synthesis of Di- and Trisubstituted Hydroxylamines
por: Hill, Jarvis, et al.
Publicado: (2023)

Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
por: Han, Hye-Suk, et al.
Publicado: (2009)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
por: Shin, Jung Won, et al.
Publicado: (2019)

A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)

Genetic and immune microenvironment characterization of HER2‐positive gastric cancer: Their association with response to trastuzumab‐based treatment
por: Kwon, Hyun Jung, et al.
Publicado: (2023)

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
por: Jung, Minkyu, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_fqsv0101qn6r1h3o9bbigp2k58